Vir Biotechnology, Inc. Amortization of Intangible Assets
Vir Biotechnology, Inc. (VIR) reported Amortization of Intangible Assets of $531.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2024-02-26
- Vir Biotechnology, Inc. amortization of intangible assets for the quarter ending 2023-12-31 was $132.00K, a 0.75% decline year-over-year.
- Vir Biotechnology, Inc. amortization of intangible assets for the quarter ending 2023-09-30 was $133.00K, a 0.00% change year-over-year.
- Vir Biotechnology, Inc. amortization of intangible assets for the quarter ending 2023-06-30 was $133.00K, a 0.00% change year-over-year.
- Vir Biotechnology, Inc. amortization of intangible assets for the quarter ending 2023-03-31 was $133.00K, a 0.00% change year-over-year.
- Vir Biotechnology, Inc. amortization of intangible assets for fiscal 2023 was $531.00K, a 0.19% decline from fiscal 2022.
- Vir Biotechnology, Inc. amortization of intangible assets for fiscal 2022 was $532.00K, a 0.19% decline from fiscal 2021.
- Vir Biotechnology, Inc. amortization of intangible assets for fiscal 2021 was $533.00K, a 48.85% decline from fiscal 2020.
- Vir Biotechnology, Inc. amortization of intangible assets for fiscal 2020 was $1.04M, a 14.80% decline from fiscal 2019.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|
| 2023-12-31 | $132.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $265.00K derived: sum of 2 quarters · filed 2024-02-26 | $398.00K derived: sum of 3 quarters · filed 2024-02-26 | $531.00K 10-K · filed 2024-02-26 |
| 2023-09-30 | $133.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $266.00K derived: sum of 2 quarters · filed 2023-11-03 | $399.00K 10-Q · filed 2023-11-03 | $532.00K derived: sum of 4 quarters · filed 2024-02-26 |
| 2023-06-30 | $133.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $266.00K 10-Q · filed 2023-08-04 | $399.00K derived: sum of 3 quarters · filed 2024-02-26 | $532.00K derived: sum of 4 quarters · filed 2024-02-26 |
| 2023-03-31 | $133.00K 10-Q · filed 2023-05-08 | $266.00K derived: sum of 2 quarters · filed 2024-02-26 | $399.00K derived: sum of 3 quarters · filed 2024-02-26 | $532.00K derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-12-31 | $133.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $266.00K derived: sum of 2 quarters · filed 2024-02-26 | $399.00K derived: sum of 3 quarters · filed 2024-02-26 | $532.00K 10-K · filed 2024-02-26 |
| 2022-09-30 | $133.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $266.00K derived: sum of 2 quarters · filed 2023-11-03 | $399.00K 10-Q · filed 2023-11-03 | $533.00K derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $133.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $266.00K 10-Q · filed 2023-08-04 | $400.00K derived: sum of 3 quarters · filed 2024-02-26 | $533.00K derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $133.00K 10-Q · filed 2023-05-08 | $267.00K derived: sum of 2 quarters · filed 2024-02-26 | $400.00K derived: sum of 3 quarters · filed 2024-02-26 | $533.00K derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $134.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $267.00K derived: sum of 2 quarters · filed 2024-02-26 | $400.00K derived: sum of 3 quarters · filed 2024-02-26 | $533.00K 10-K · filed 2024-02-26 |
| 2021-09-30 | $133.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $266.00K derived: sum of 2 quarters · filed 2022-11-03 | $399.00K 10-Q · filed 2022-11-03 | $523.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $133.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $266.00K 10-Q · filed 2022-08-09 | $390.00K derived: sum of 3 quarters · filed 2023-02-28 | $696.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $133.00K 10-Q · filed 2022-05-05 | $257.00K derived: sum of 2 quarters · filed 2023-02-28 | $563.00K derived: sum of 3 quarters · filed 2023-02-28 | $869.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $124.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $430.00K derived: sum of 2 quarters · filed 2023-02-28 | $736.00K derived: sum of 3 quarters · filed 2023-02-28 | $1.04M 10-K · filed 2023-02-28 |
| 2020-09-30 | $306.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $612.00K derived: sum of 2 quarters · filed 2021-11-04 | $918.00K 10-Q · filed 2021-11-04 | $1.22M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $306.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $612.00K 10-Q · filed 2021-08-05 | $917.00K derived: sum of 3 quarters · filed 2022-02-28 | $1.22M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $306.00K 10-Q · filed 2021-05-06 | $611.00K derived: sum of 2 quarters · filed 2022-02-28 | $917.00K derived: sum of 3 quarters · filed 2022-02-28 | $1.22M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $305.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $611.00K derived: sum of 2 quarters · filed 2022-02-28 | $917.00K derived: sum of 3 quarters · filed 2022-02-28 | $1.22M 10-K · filed 2022-02-28 |
| 2019-09-30 | $306.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $612.00K derived: sum of 2 quarters · filed 2020-11-10 | $918.00K 10-Q · filed 2020-11-10 | $1.22M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $306.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $612.00K 10-Q · filed 2020-08-11 | $917.00K derived: sum of 3 quarters · filed 2021-02-25 | |
| 2019-03-31 | $306.00K 10-Q · filed 2020-05-12 | $611.00K derived: sum of 2 quarters · filed 2021-02-25 | ||
| 2018-12-31 | $305.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $1.14M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | $833.00K 10-Q · filed 2019-11-19 | |||
| 2017-12-31 | $177.00K 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |